Skip to main content
Signal8

REVELATION BIOSCIENCES, INC. (REVB) Form 8-K — Jun 24, 2026

$REVBForm 8-KItems 5.02, 5.03, 5.07, 9.01Filed Jun 24, 2026, 4:47 PM ET0001193125-26-281200Original filing

Revelation Biosciences announced that stockholders approved a proposal granting the Board discretionary authority to effect a reverse stock split of the company's common stock at a ratio ranging from 1-for-2 to 1-for-250 within the next year. This authority is often utilized by small-cap companies to maintain compliance with minimum bid price listing requirements on Nasdaq. The company also entered into amended employment agreements with CEO James Rolke and CFO Chester S. Zygmont, increasing change-in-control severance benefits to two times the sum of base salary and target bonus.

Key figures

Shares outstanding
3908420
Severance multiplier
2
Votes for reverse split
1786623
Reverse split ratio range
1-for-2 to 1-for-250
Severance coverage months
18
Director election votes for
519169
Votes abstain reverse split
3410
Votes against reverse split
444315
Director election votes against
24779
Director election votes withheld
263081

Price after filing

1 day: -6.8%7 days: 0.0%30 days: +3.9%

Close on the filing date to close N calendar days later (from $1.03). Historical, not a forecast.

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.